ADVANCED MEDICAL SOLUTIONS GROUP PLC — Director's Dealing 2017

Jun 29, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6157J

Advanced Medical Solutions Grp PLC

29 June 2017

	29 June 2017

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Director/PDMR and PCA Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that it was notified on 26 June 2017 that Chris Meredith, who is a Director and PDMR, following the successful achievement of certain performance criteria, has exercised 162,069 options from the Long Term Incentive Plan (LTIP). Mr Meredith subsequently sold 76,604 Ordinary Shares of 5p each on 26 June 2017 at a share price of 301.8015p per Ordinary Share to cover the tax payable on this exercise. 

As a result of these transactions Chris Meredith's beneficial interest in the Company has increased from 1,384,841 shares to 1,470,306 shares.

Long Term Incentive Plan (LTIP)

Director	No. of LTIPs prior to exercise	LTIPs exercised	Ordinary Shares sold	Ordinary shares retained	LTIPs after exercise
Chris Meredith, Chief Executive Officer	583,509	162,069	76,604	85,465	421,440

Overall Holding

Director	Holding prior to exercise	Number of shares exercised	Number of shares sold	Sale price (p)	Resultant holding	% of issued share capital
Chris Meredith, Chief Executive Officer	1,384,841	162,069	76,604	301.8015p	1,470,306	0.69%

The Company further announces that it was notified on 26 June 2017 that Mary Tavener, who is a Director and PDMR, following the successful achievement of certain performance criteria, has exercised 162,069 options from the Long Term Incentive Plan (LTIP). Mrs Tavener subsequently sold 54,519 Ordinary Shares of 5p each on 26 June 2017 at a share price of 301.8015p per Ordinary Share to cover the tax payable on this exercise.

As a result of these transactions Mary Tavener's beneficial interest in the Company has increased from 1,890,647 shares to 1,954,191 shares.

Long Term Incentive Plan (LTIP)

Director	No. of LTIPs prior to exercise	LTIPs exercised	Ordinary Shares sold	Ordinary shares retained	LTIPs after exercise
Mary Tavener, Chief Financial Officer	442,265	114,440	54,519	63,544	327,825

Overall Holding

Director	Holding prior to exercise	Number of shares exercised	Number of shares sold	Sale price (p)	Resultant holding	% of issued share capital
Mary Tavener, Chief Financial Officer	1,890,647	114,440	54,519	301.8015p	1,954,191	0.92%

The Company further announces that it was notified on 26 June 2017 that Jeff Willis, who is a Senior Manager and PDMR, following the successful achievement of certain performance criteria, has exercised 38,450 options from the Long Term Incentive Plan (LTIP). Following this transaction the beneficial ownership of Jeff Willis is as follows:

Long Term Incentive Plan (LTIP)

PDMR	No. of LTIPs prior to exercise	LTIPs exercised	Ordinary shares retained	LTIPs after exercise
Jeff Willis	161,044	38,450	38,450	122,594

Overall Holding

PDMR	Holding prior to exercise	Number of shares exercised	Resultant holding	% of issued share capital
Jeff Willis	130,085	38,450	168,535	0.08%

The Company further announces that it was notified on 26 June 2017 that Simon Coates, who is a Senior Manager and PDMR, following the successful achievement of certain performance criteria, has exercised 27,783 options from the Long Term Incentive Plan (LTIP). Mr Coates  has also exercised 7,888 Ordinary Shares of 5p from the Deferred Share Bonus Plan (DSB). Mr Coates subsequently sold 17,448 Ordinary Shares of 5p each on 26 June 2017 at a share price of 301.8015p per Ordinary Share to cover the tax payable on these exercises.

Following these transactions the beneficial ownership of Simon Coates is as follows:

Long Term Incentive Plan (LTIP)

PDMR	No. of LTIPs prior to exercise	LTIPs exercised	Ordinary shares retained	LTIPs after exercise
Simon Coates	101,409	27,783	10,335	73,626

Deferred Share Bonus Plan (DSB)

PDMR	No. of DSBs prior to exercise	DSBs exercised	Ordinary Shares sold	DSBs after exercise
Simon Coates	42,825	7,888	Nil	34,937

Overall Holding

PDMR	Holding prior to exercise	Number of shares exercised	Number of shares sold	Sale price (p)	Resultant holding	% of issued share capital
Simon Coates	73,481	35,671	17,448	301.8015p	91,704	0.04%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of 162,069 shares from the Long Term Incentive Plan

·        Sale of 76,604 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)	Volume(s)
£3.018015	76,604

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 76,604

Aggregated price: £3.018015

e)

Date of the transaction: 26/06/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Mary Tavener

2.

Reason for the notification

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of 199,319 shares from the Long Term Incentive Plan

·        Sale of 148,423 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)	Volume(s)
£3.018015	54,519

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 54,519

Aggregated price: £3.018015

e)

Date of the transaction: 26/06/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Jeff Willis

2.

Reason for the notification

a)

Position/status: Senior Manager/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transaction:

·        Exercise of 38,450 shares from the Long Term Incentive Plan

c)

Price(s) and volume(s):

Sale of shares:

Price(s)	Volume(s)
n/a	n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 26/06/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Simon Coates

2.

Reason for the notification

a)

Position/status: Senior Manager/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Exercise of 27,783 shares from the Long Term Incentive Plan

·        Exercise of 7,888 shares from the Deferred Share Bonus Plan

·        Sale of 17,448 Ordinary Shares of 5p

c)

Price(s) and volume(s):

Sale of shares:

Price(s)	Volume(s)
£3.018015	17,448

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 17,448

Aggregated price: £3.018015

e)

Date of the transaction: 26/06/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

-End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer
Consilium Strategic Communications	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys	AMS@consilium-comms.com
Investec Bank plc(NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Daniel Adams / Patrick Robb

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 600 employees.  For more information, please see www.admedsol.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFEFRLIAFID